In this issue:
Novel inflammatory biomarkers in hidradenitis suppurativa
Risk of heart failure with TNF inhibitors
Omalizumab dosing and drug survival for chronic spontaneous urticaria
Early termination of adjuvant immunotherapy in melanoma
Dupilumab in papuloerythroderma of Ofuji
Bimekizumab for moderate-to-severe hidradenitis suppurativa
Long-term dupilumab in paediatric atopic dermatitis
Eczematous eruption with biological agents
Dupilumab as a therapeutic option in autoimmune bullous diseases
Prognostic anti-PD-1 biomarkers for advanced melanoma
Please login below to download this issue (PDF)